NIHR funded clinical pilot
We are excited to announce that as part of a National Institute of Health and Care Research (NIHR) funded study and in partnership with Queen Mary University of London (QMUL) and Barts Health we have just started a prospective clinical pilot study to gather additional evidence to support the clinical adoption of one of our first products, offering accurate diagnosis and outcome prognosis in dementia. Using only standard structural (T1) MRI scans from 1.5 and 3 tesla MRI scanners which are commonly acquired in the UK dementia pathway, AINOSTICS' solution has been shown to be able to diagnose individuals with Alzheimer's disease with an accuracy of 97%, and predict the risk of conversion to Alzheimer's disease in individuals classed as having mild cognitive impairment (MCI) with an accuracy of 92% and up to 7 years prior to their definitive clinical diagnosis.
The funding was awarded under the NIHR Invention for Innovation (i4i) programme, which is a translational research funding scheme aimed at de-risking early-to-late stage medical devices, in vitro diagnostics and high-impact patient-focused digital health technologies for ultimate NHS use. The Programme funds projects that have demonstrated proof-of-concept and have a clear pathway towards adoption and commercialisation.
Dr Hojjat Azadbakht, CEO of AINOSTICS, stated that "we are thrilled to be working with our collaborators at QMUL and Barts Health to deliver the remaining evidence needed to ensure the successful clinical adoption of the solution, which has the potential to revolutionise dementia diagnosis and care".
Dr Charles Marshall (Consultant Neurologist at Barts Health and Clinical Senior Lecturer in Neurology at QMUL) who will lead the study stated that "we are really excited to be embarking on this project that we hope will be instrumental in levelling up dementia diagnosis in the NHS. We urgently need new technologies like this to deliver more timely and accurate diagnosis in memory clinics, and to ensure that access to diagnosis is not influenced by ethnicity, postcode or socio-economic status. This will help to prepare the NHS to deliver future treatments for dementia as equitably as possible once they become available".